PhoreMost expands into new facility  

PhoreMost it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, designed to support PhoreMost’s phenotypic screening requirements and expertise. The new facility enables the company to add in-house flow cytometry and imaging capabilities. 

Dr Chris Torrance, CEO of PhoreMost, said: “Our move to Unity Campus follows a significant year for the company, including a successful £33M Series B investment round in March 2021. As a team, remaining within the Cambridge biotech cluster is important, to help fuel new strategic collaborations, and support those already in progress. This move brings the whole team together in one site, where previously we were split across two buildings. With further space available at Unity Campus, we are well-positioned to continue to advance and expand our drug discovery programmes across high value, but under-served, therapeutic areas.” 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free